L. Renfro

Daniel J Sargent, Christophe Tournigand, Eduardo Diaz-Rubio, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.

R. Labianca, J. Meyerhardt, D. Sargent, 2017 .

Surrogate End Points in Soft Tissue Sarcoma: Methodologic Challenges.

D. Sargent, Q. Shi, L. Renfro, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of the First Generation of Children's Oncology Group Clinical Trials on Clinical Practice for Wilms Tumor.

M. Chintagumpala, J. Dome, P. Grundy, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database.

D. Sargent, M. Shah, D. Haller, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D3 levels and survival among patients with metastatic colorectal cancer

J. Meyerhardt, H. McLeod, C. Fuchs, 2019, Cancer Causes & Control.

Trial Design Challenges and Approaches for Precision Oncology in Rare Tumors: Experiences of the Children's Oncology Group.

T. Alonzo, Lingyun Ji, J. Kairalla, 2019, JCO precision oncology.

Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database.

D. Sargent, C. Bokemeyer, E. Van Cutsem, 2018, European journal of cancer.

ORGAN PRESERVATION FOR CLINICAL T2N0 DISTAL RECTAL CANCER USING NEOADJUVANT CHEMORADIOTHERAPY AND LOCAL EXCISION: RESULTS OF A MULTICENTER PHASE 2 STUDY

P. Cataldo, E. Chan, A. Pigazzi, 2015, The Lancet. Oncology.

Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patients.

S. Dakhil, S. Alberts, M. Lopatin, 2014, The oncologist.

Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer.

Jesse S. Voss, James X. Sun, A. Grothey, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Definitions and statistical properties of master protocols for personalized medicine in oncology

Sumithra J Mandrekar, Lindsay A Renfro, S. Mandrekar, 2018, Journal of biopharmaceutical statistics.

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

R. Labianca, J. Meyerhardt, D. Sargent, 2018, The New England journal of medicine.

Point estimation following two‐stage adaptive threshold enrichment clinical trials

Nigel Stallard, Susan Todd, Peter K Kimani, 2018, Statistics in medicine.

Chronic consequences of acute injuries: Worse survival after discharge

D. Ballard, S. Shafi, L. Gentilello, 2012, The journal of trauma and acute care surgery.

Comparative Economics of a 12-Gene Assay for Predicting Risk of Recurrence in Stage II Colon Cancer

J. Hornberger, S. Dakhil, S. Alberts, 2014, PharmacoEconomics.

Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program.

D. Sargent, R. Goldberg, L. Saltz, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database.

C. Tournigand, D. Sargent, C. Bokemeyer, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MRE11-Deficiency Associated with Improved Long-Term Disease Free Survival and Overall Survival in a Subset of Stage III Colon Cancer Patients in Randomized CALGB 89803 Trial

M. Bertagnolli, M. Emond, P. Rabinovitch, 2014, PloS one.

ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer.

Daniel J Sargent, Greg Yothers, Lindsay A Renfro, 2014, Journal of the National Cancer Institute.

Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project

C. Tournigand, D. Sargent, R. Simes, 2018, Journal of the National Cancer Institute.

Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database.

R. Labianca, D. Kerr, D. Sargent, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Genetic and Epigenetic Features of Bilateral Wilms Tumor Predisposition: A Report from the Children's Oncology Group AREN18B5-Q Study

Heather L. Mulder, B. Crompton, Zhaoming Wang, 2023, Research square.

Center-within-trial versus trial-level evaluation of surrogate endpoints

Yuan Xue, Qian Shi, Junlong Li, 2014, Comput. Stat. Data Anal..

On the need to adjust for multiplicity in confirmatory clinical trials with master protocols

S. Todd, S. Todd, N. Stallard, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database.

R. Labianca, D. Sargent, E. Van Cutsem, 2016, Journal of geriatric oncology.

Precision oncology: A new era of cancer clinical trials.

Sumithra J Mandrekar, Lindsay A Renfro, Ming-Wen An, 2017, Cancer letters.

Targeted therapies in oncology: perspectives on trial designs and practical considerations

S. Mandrekar, L. Renfro, 2015 .

Adaptive randomized phase II design for biomarker threshold selection and independent evaluation.

D. Sargent, L. Renfro, A. Grothey, 2014, Chinese clinical oncology.

Adaptive randomized phase II design for biomarker threshold selection and independent evaluation.

Daniel J Sargent, Lindsay A Renfro, D. Sargent, 2014, Chinese clinical oncology.

Bayesian adjusted R2 for the meta‐analytic evaluation of surrogate time‐to‐event endpoints in clinical trials

Bradley P Carlin, Daniel J Sargent, Qian Shi, 2012, Statistics in medicine.

Multitrial evaluation of progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in previously untreated extensive-stage small cell lung cancer (ES-SCLC): An Alliance-led analysis.

S. Mandrekar, D. Gandara, K. Ding, 2013 .

Impact of Copula Directional Specification on Multi-Trial Evaluation of Surrogate End Points

Daniel J Sargent, Hongwei Shang, Lindsay A Renfro, 2015, Journal of biopharmaceutical statistics.

The impact of young age on survival in patients with metastatic colorectal cancer: Analysis from the ARCAD Clinical Trials Program

D. Sargent, R. Goldberg, L. Saltz, 2013 .

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer

Lindsay A. Renfro, Herbert I. Hurwitz, L. Diaz, 2017, Clinical Cancer Research.

Point and interval estimation in two-stage adaptive designs with time to event data and biomarker-driven subpopulation selection

Nigel Stallard, Susan Todd, Ekkehard Glimm, 2020, Statistics in medicine.

Children's Oncology Group's 2023 blueprint for research: Renal tumors

L. Renfro, J. Geller, A. Hong, 2023, Pediatric blood & cancer.

CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.

M. Bertagnolli, M. Emond, R. Goldberg, 2014, Gastroenterology.

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

R. Labianca, J. Meyerhardt, D. Sargent, 2018, The New England journal of medicine.

Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D3 levels and survival among patients with metastatic colorectal cancer

J. Meyerhardt, H. McLeod, C. Fuchs, 2019, Cancer Causes & Control.

Comparative assessment of trial-level surrogacy measures for candidate time-to-event surrogate endpoints in clinical trials

Qian Shi, Tomasz Burzykowski, Brian M. Bot, 2011, Comput. Stat. Data Anal..

Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer

S. Mandrekar, E. Vokes, A. Adjei, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.